Peptide therapy TikTok claims: separating hype from human data

What did @teawithpee actually say?

The creator isn't making clinical claims here, which is worth noting upfront. She's recruiting women into a private community to share peptide experiences, side effects, and results. She calls it "research purposes only" and frames it as a support group for people who feel alone navigating peptide use.

The core pitch: peptides are "taking over the world," information is hard to find, dosing is confusing, and community helps. She acknowledges the space feels "taboo" and that there's not a lot of reliable information out there. She also mentions having a "source" she trusts, which in peptide circles typically means a research chemical supplier or compounding pharmacy operating in a gray area. She doesn't name it. That matters.

She's not claiming a specific peptide cures anything. She's saying optimization is real, it's working, and she wants other women to join her on the journey. The ask is community, not clinical advice. But the framing around that ask deserves scrutiny.

Does the science back this up?

The claim that peptide therapy is broadly "working" for optimization is where things get complicated fast. Some peptides have real, peer-reviewed evidence behind them. Many do not, at least not in humans.

BPC-157 has shown tissue repair and anti-inflammatory effects in rodent models (Sikiric et al., 2018, Current Pharmaceutical Design), but there are no completed human clinical trials. GHK-Cu has some evidence for skin and wound healing (Pickart et al., 2015, Journal of Aging Science), but "optimization" claims go well beyond what the data supports. Growth hormone secretagogues like ipamorelin and CJC-1295 do stimulate GH release in clinical settings (Raun et al., 1998, European Journal of Endocrinology), but they're not approved for general wellness use in the US.

MK-677, commonly lumped in with peptides, is actually a small molecule, not a peptide, and carries documented risks including increased cortisol, insulin resistance, and edema (Murphy et al., 1998, Journal of Clinical Endocrinology and Metabolism). The gap between "this is being used" and "this is proven safe" in healthy people is enormous across this category.

What did they get wrong (or right)?

She gets one thing right: the information environment is genuinely chaotic. Dosing guidance for most of these compounds doesn't exist in any regulatory or clinical framework for healthy adults, because they haven't been studied that way. People are figuring it out on forums and group chats, which is exactly what she's describing.

She gets something importantly wrong in the framing. Calling a private group chat "research purposes only" doesn't make it research. Real research has IRB oversight, informed consent protocols, and adverse event reporting. A group of women sharing injection experiences on a private platform is anecdotal peer exchange, which can be valuable for community support but should not be confused with evidence generation.

The phrase "we want to see that this actually is working, which it is" is the most problematic line. She's asserting efficacy as settled when it isn't, at least not for most use cases she's gesturing toward. Confirmation bias in wellness communities is well-documented (Kata, 2012, Vaccine), and private groups that select for enthusiasts are particularly prone to it.

What should you actually know?

If you're considering peptide therapy, the most important thing to understand is the regulatory gap you're operating in. Most peptides discussed in biohacking communities are not FDA-approved for the uses being promoted. Some are available through licensed compounding pharmacies with a physician's prescription. Others are sold as "research chemicals" with labeling that explicitly states they're not for human use, even when that's exactly how they're being used.

The "source" question matters enormously. Purity, sterility, and accurate dosing in unregulated peptide products are not guaranteed. A 2020 analysis of research peptides found significant variability in actual peptide content compared to labeled amounts (Kjaer et al., 2020, Drug Testing and Analysis).

Community support is genuinely useful for people navigating complex health decisions. The problem is when community replaces clinical oversight. Side effects like fatigue, which she mentions, can signal real physiological responses that warrant medical evaluation, not just a group chat poll. If you're injecting compounds that affect growth hormone, inflammation, or tissue repair, you should have a clinician monitoring your baseline labs and response. Full stop.